Clinical trials have confirmed that anti-angiogenesis agents like bevacizumab and ramucirumab combined with EGFR-TKI could significantly prolong the survival of patients with EGFR-mutant NSCLC (Herbst et al., 2011; Nakagawa et al., 2019; Ninomiya et al., 2019; Zhou Q. et al., 2021). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.